We chose to focus on the only commercially available biomarker test for AKI in the US because it is also available worldwide and has a published high-specificity cutoff and because an ongoing trial is already using it specifically for patients with sepsis.28 Future work is needed to evaluate other potential biomarkers alone or in combination to augment AKI staging, such as kidney injury molecule 1 and neutrophil gelatinase–associated lipocalin. This evidence concerns the gene HAVCR1 and Sepsis.